NASDAQ:RAIN Rain Oncology (RAIN) Stock Forecast, Price & News $0.86 +0.01 (+1.17%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$0.84▼$0.8750-Day Range$0.82▼$1.4152-Week Range$0.82▼$14.48Volume185,618 shsAverage Volume146,009 shsMarket Capitalization$31.35 millionP/E RatioN/ADividend YieldN/APrice Target$17.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Rain Oncology MarketRank™ ForecastAnalyst RatingHold2.17 Rating ScoreUpside/Downside1,872.6% Upside$17.00 Price TargetShort InterestHealthy3.47% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.20Based on 11 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.67) to ($0.72) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.25 out of 5 starsMedical Sector372nd out of 972 stocksPharmaceutical Preparations Industry154th out of 445 stocks 3.1 Analyst's Opinion Consensus RatingRain Oncology has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 2 buy ratings, 10 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.00, Rain Oncology has a forecasted upside of 1,872.6% from its current price of $0.86.Amount of Analyst CoverageRain Oncology has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.47% of the float of Rain Oncology has been sold short.Short Interest Ratio / Days to CoverRain Oncology has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Rain Oncology has recently decreased by 18.11%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldRain Oncology does not currently pay a dividend.Dividend GrowthRain Oncology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RAIN. Previous Next 1.0 News and Social Media Coverage News SentimentRain Oncology has a news sentiment score of -0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Rain Oncology this week, compared to 5 articles on an average week.Search InterestOnly 2 people have searched for RAIN on MarketBeat in the last 30 days. This is a decrease of -78% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Rain Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rain Oncology insiders have not sold or bought any company stock.Percentage Held by Insiders17.40% of the stock of Rain Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions65.84% of the stock of Rain Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Rain Oncology are expected to grow in the coming year, from ($1.67) to ($0.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rain Oncology is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rain Oncology is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRain Oncology has a P/B Ratio of 0.28. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Rain Oncology (NASDAQ:RAIN) StockRain Oncology Inc., a late-stage precision oncology company, engages in developing therapies that target oncogenic drivers to genetically select patients in the United States. The company's lead product candidate is milademetan, a small molecule oral inhibitor of MDM2-p53 complex that reactivates p53. The company was formerly known as Rain Therapeutics Inc. and changed its name to Rain Oncology Inc. in December 2022. Rain Oncology Inc. was incorporated in 2017 and is headquartered in Newark, California.Read More RAIN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RAIN Stock News HeadlinesOctober 1, 2023 | msn.comWinship 5K to support local cancer researchSeptember 29, 2023 | msn.comVoluntary relocation fund created for Houston-area residents living near cancer clusterOctober 1, 2023 | Porter and Company (Ad)Top Analyst Exposes Imminent Crisis Hurtling Towards AmericaThe man who warned of the dot-com blow up, the 2008 housing collapse, and the loss of America’s AAA rating makes a shocking prediction…September 28, 2023 | news.yahoo.comTiny plastic particles have reached clouds, contaminating ‘everything we eat’ via rain, study warnsSeptember 27, 2023 | news.yahoo.comMorning sprinkles followed by strong storms and heavy rain in the afternoonSeptember 27, 2023 | msn.comBingo for Breast Cancer fundraiser happening ThursdaySeptember 26, 2023 | msn.comProstate cancer awareness month underscores importance of getting screenedSeptember 25, 2023 | msn.com‘Today' show's Craig Melvin, celebs raise $1.2 million in CT to fight colorectal cancerOctober 1, 2023 | Porter and Company (Ad)Top Analyst Exposes Imminent Crisis Hurtling Towards AmericaThe man who warned of the dot-com blow up, the 2008 housing collapse, and the loss of America’s AAA rating makes a shocking prediction…September 25, 2023 | msn.comCancer institute asks for help over limited spaceSeptember 25, 2023 | msn.comIowa Gov. Kim Reynolds’ husband diagnosed with lung cancerSeptember 25, 2023 | msn.comFIRST ALERT FORECAST: Rain Expected as we Begin our WorkweekSeptember 23, 2023 | msn.comBlue September: Bay of Plenty prostate cancer survivor urges men to get a PSA testSeptember 22, 2023 | msn.comSteady rain Saturday in southern New Hampshire; track of Potential Tropical Cyclone 16 being watchedSeptember 21, 2023 | msn.comRain ahead; Standing Rock poor roads; lion statue stolenSeptember 21, 2023 | mirror.co.uk'Cancer nearly took everything from me - now I'm hiking up mountains'September 21, 2023 | americanbankingnews.comRain Oncology Inc. (NASDAQ:RAIN) Receives $17.00 Average Price Target from BrokeragesSeptember 20, 2023 | usatoday.comArsenal makes winning return to Champions League by beating PSV Eindhoven 4-0 in the rainSeptember 18, 2023 | msn.comMichigan cancer survivor inspires other kids battling cancerSeptember 18, 2023 | msn.comCitigroup Maintains Rain Oncology (RAIN) Neutral RecommendationSeptember 14, 2023 | uk.finance.yahoo.com‘No rain, no winter, no rivers’: This ancient European lake is receding - and it could be disastrousSeptember 12, 2023 | news.yahoo.comAtmospheric acid test: Can the successes of reducing acid rain apply to the current climate crisis?September 12, 2023 | msn.comJonnie Irwin Spending Time with Family Despite Being 'Pretty Unwell' amid Terminal CancerSeptember 11, 2023 | stockhouse.comThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Rain Oncology Inc. (RAIN)September 11, 2023 | markets.businessinsider.comSHAREHOLDER ALERT: Potential Recovery for Rain Oncology Inc. (RAIN) Investors Affected by Stock Drop - Levi & Korsinsky Pursuing Class Action LawsuitSeptember 11, 2023 | uk.news.yahoo.comEnvirovue colleagues complete Three Peaks Challenge for cancer charitySeptember 10, 2023 | msn.comDoctors warn of the most common areas of the body for skin cancer symptoms to appearSee More Headlines Receive RAIN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rain Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address RAIN Company Calendar Last Earnings8/10/2023Today10/01/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RAIN CUSIPN/A CIK1724979 Webwww.rainthera.com Phone510-953-5559FaxN/AEmployees63Year FoundedN/APrice Target and Rating Average Stock Price Forecast$17.00 High Stock Price Forecast$24.00 Low Stock Price Forecast$11.00 Forecasted Upside/Downside+1,872.6%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($2.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-75,720,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-91.93% Return on Assets-76.44% Debt Debt-to-Equity RatioN/A Current Ratio4.96 Quick Ratio4.96 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.11 per share Price / Book0.28Miscellaneous Outstanding Shares36,376,000Free Float30,047,000Market Cap$31.35 million OptionableNot Optionable Beta0.21 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Avanish Vellanki M.B.A. (Age 48)Co-Founder, CEO & Chairman Comp: $959.75kDr. Robert C. Doebele M.D. (Age 52)Ph.D., Co-Founder, Chairman of Scientific Advisory Board, Pres & CSO and Chief Medical Officer Comp: $700.56kMs. Josephine Bruce (Age 44)Principal Financial & Accounting officer Ms. Theresa O'Connell M.S.Director of Corp. Devel. & OperationsMr. Erik Atkisson (Age 51)Gen. Counsel & Chief Compliance Officer Ms. Charmi TurnerVP of People & CultureMs. Vijaya Tirunagaru Ph.D.Sr. VP & Head of ResearchDr. Nora Ku M.D.MD & VP of Clinical Devel.More ExecutivesKey CompetitorsCumberland PharmaceuticalsNASDAQ:CPIXTherapeuticsMDNASDAQ:TXMDBiora TherapeuticsNASDAQ:BIORASLAN PharmaceuticalsNASDAQ:ASLNPieris PharmaceuticalsNASDAQ:PIRSView All CompetitorsInsiders & InstitutionsGoldman Sachs Group Inc.Bought 153,534 shares on 8/15/2023Ownership: 0.656%Alliancebernstein L.P.Bought 42,580 shares on 8/15/2023Ownership: 0.117%Citadel Advisors LLCBought 28,300 shares on 8/15/2023Ownership: 0.000%Walleye Capital LLCBought 300 shares on 8/15/2023Ownership: 0.000%Walleye Trading LLCBought 300 shares on 8/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions RAIN Stock - Frequently Asked Questions Should I buy or sell Rain Oncology stock right now? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rain Oncology in the last year. There are currently 10 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" RAIN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RAIN, but not buy additional shares or sell existing shares. View RAIN analyst ratings or view top-rated stocks. What is Rain Oncology's stock price forecast for 2023? 12 analysts have issued twelve-month price targets for Rain Oncology's stock. Their RAIN share price forecasts range from $11.00 to $24.00. On average, they predict the company's stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 1,872.6% from the stock's current price. View analysts price targets for RAIN or view top-rated stocks among Wall Street analysts. How have RAIN shares performed in 2023? Rain Oncology's stock was trading at $8.00 at the start of the year. Since then, RAIN stock has decreased by 89.2% and is now trading at $0.8618. View the best growth stocks for 2023 here. Are investors shorting Rain Oncology? Rain Oncology saw a decrease in short interest during the month of September. As of September 15th, there was short interest totaling 705,700 shares, a decrease of 18.1% from the August 31st total of 861,800 shares. Based on an average trading volume of 302,100 shares, the short-interest ratio is presently 2.3 days. Approximately 3.5% of the company's stock are short sold. View Rain Oncology's Short Interest. When is Rain Oncology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our RAIN earnings forecast. How were Rain Oncology's earnings last quarter? Rain Oncology Inc. (NASDAQ:RAIN) announced its quarterly earnings results on Thursday, August, 10th. The company reported ($0.61) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by $0.12. What ETFs hold Rain Oncology's stock? ETFs with the largest weight of Rain Oncology (NASDAQ:RAIN) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR), Horizon Kinetics Medical ETF (MEDX), When did Rain Oncology IPO? (RAIN) raised $126 million in an initial public offering (IPO) on Friday, April 23rd 2021. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Citigroup, Piper Sandler and Guggenheim Securities acted as the underwriters for the IPO. What is Rain Oncology's stock symbol? Rain Oncology trades on the NASDAQ under the ticker symbol "RAIN." How do I buy shares of Rain Oncology? Shares of RAIN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Rain Oncology's stock price today? One share of RAIN stock can currently be purchased for approximately $0.86. How much money does Rain Oncology make? Rain Oncology (NASDAQ:RAIN) has a market capitalization of $31.35 million. The company earns $-75,720,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. How can I contact Rain Oncology? The official website for the company is www.rainthera.com. The company can be reached via phone at 510-953-5559 or via email at bob@lifesciadvisors.com. This page (NASDAQ:RAIN) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rain Oncology Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.